24.06 09:12 | dpa-AFX: Takeda Announces Approval Of LIVTENCITY In Japan |
24.06 09:04 | dpa-AFX: *TAKEDA GETS APPROVAL FOR LIVTENCITY IN JAPAN FOR REFRACTORY POST-TRANSPLANT CMV INFECTION/DISEASE |
21.06 14:56 | dpa-AFX: Health Canada Approves Takeda's HyQvia For Immunodeficiencies In Pediatric Patients |
21.06 14:05 | dpa-AFX: *TAKEDA CANADA GETS APPROVAL FOR HYQVIA AS PRIMARY & SECONDARY IMMUNODEFICIENCY REPLACEMENT THERAPY IN PEDIATRIC PATIENTS |
18.06 15:17 | dpa-AFX: Takeda Presents Long-Term Data From Phase 3 ADVANCE-CIDP 3 Trial Of HYQVIA In CIDP Patients |
18.06 14:06 | dpa-AFX: *TAKEDA REPORTS POSITIVE LONG-TERM RESULTS FOR HYQVIA IN CIDP MAINTENANCE TREATMENT |
17.06 15:29 | dpa-AFX: *OVID THERAPEUTICS REPORTS ON TAKEDA'S ANNOUNCEMENT OF PHASE 3 NEGATIVE RESULTS FOR SOTICLESTAT |
14.06 14:43 | dpa-AFX: Takeda Signs Option Agreement With Ascentage For Exclusive License For Olverembatinib |
14.06 14:06 | dpa-AFX: *TAKEDA SECURES EXCLUSIVE GLOBAL LICENSE OPTION FOR OLVEREMBATINIB FROM ASCENTAGE PHARMA |
07.06 05:12 | dpa-AFX: Former Takeda Employee Pleads Guilty To $2.3 Mln Embezzlement Scheme |
31.05 18:58 | dpa-AFX: Takeda Gets Positive CHMP Feedback For Recombinant ADAMTS13 |
31.05 17:23 | dpa-AFX: *TAKEDA GETS POSITIVE CHMP OPINION FOR RECOMBINANT ADAMTS13 |
16.05 16:42 | dpa-AFX: Takeda Canada Finalises LoI With PCPA For Antiviral Drug Livtencity |
16.05 14:07 | dpa-AFX: *TAKEDA CANADA CONCLUDES LOI WITH PCPA FOR LIVTENCITY IN ADULT POST-TRANSPLANT CMV TREATMENT |
13.05 12:36 | dpa-AFX: Takeda, AC Immune Sign License Agreement For Active Immunotherapy For Alzheimer's Disease |
13.05 12:05 | dpa-AFX: *AC IMMUNE, TAKEDA SIGN LICENSE AGREEMENT FOR ACTIVE IMMUNOTHERAPY TARGETING AMYLOID BETA FOR ALZHEIMER'S DISEASE |
09.05 09:20 | dpa-AFX: Takeda Full-year Profit Declines, But Revenue Ascends |
09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY CORE OPERATING PROFIT 1.188 TRLN YEN VS. 1.054 TRLN YEN LAST YEAR |
09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY NET INCOME 317.04 BLN YEN VS. 144.20 BLN YEN LAST YEAR |
09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY PRE-TAX INCOME 375.09 BLN YEN VS. 52.79 BLN YEN LAST YEAR |
|